Parkin Tablet contains Trihexyphenidyl, an anticholinergic medication primarily used to manage symptoms of Parkinson’s disease and drug-induced extrapyramidal disorders. By inhibiting acetylcholine activity in the brain, it helps alleviate tremors, rigidity, and bradykinesia, improving motor control and quality of life for patients. DrugBank
Key Benefits & Uses
-
Parkinson’s Disease Management: Reduces tremors, stiffness, and slow movements associated with Parkinson’s disease. Drugs.com
-
Drug-Induced Extrapyramidal Symptoms: Alleviates movement disorders caused by antipsychotic medications. Drugs.com
-
Dystonia Treatment: Eases muscle spasms and abnormal postures in conditions like cerebral palsy.
-
Antidote for Organophosphate Poisoning: More effective than atropine in counteracting cholinergic crises. Wikipedia
How to Use
Take Parkin Tablet orally, with or without food. For Parkinson’s disease, it is typically administered in divided doses throughout the day. The exact dosage and frequency should be determined by a healthcare provider based on individual needs. Cleveland Clinic
Important Safety Information
-
Contraindications: Not recommended for individuals with narrow-angle glaucoma, obstructive uropathy, or myasthenia gravis. Wikipedia
-
Caution in Elderly: Older adults may experience heightened sensitivity to side effects. Cleveland Clinic
-
Pregnancy Category: Consult a healthcare provider before use during pregnancy.
Common Side Effects
-
Central Nervous System: Dizziness, blurred vision, headache. MedlinePlus
-
Gastrointestinal: Dry mouth, constipation, nausea. MedlinePlus
-
Urinary: Difficulty urinating. MedlinePlus
-
Others: Confusion, especially in elderly patients. Wikipedia
Why Choose Parkin Tablet
Parkin Tablet offers a cost-effective solution for managing Parkinson’s disease and related movement disorders. Manufactured under stringent quality controls, it ensures consistent efficacy and safety. Consult with a healthcare provider to determine if Parkin Tablet is suitable for your treatment regimen.

